Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:38:28.949Z.
Consensus retrieved: 2026-10-06T16:17:37.043Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:38:28.949Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0bb308cc02f92ae7022b98057b1ab9be430f0ff9c4f6ee28c48a1717489dc78b
Forward PE Ratio (N/A) = Dated Quote Price ($8.56) / Consensus Forward EPS ($-0.64)
FORWARD PE RATIO
N/A
Sight Sciences, Inc.
Market Cap
$465.75M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Sight Sciences, Inc. (SGHT) | $465.75M | N/A |
| Kamada Ltd. (KMDA)vs › | $467.90M | 16.98 |
| Alpha Teknova, Inc. (TKNO)vs › | $469.12M | N/A |
| Cerus Corporation (CERS)vs › | $471.57M | N/A |
| Arvinas, Inc. (ARVN)vs › | $471.65M | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.23M | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | N/A |
| NRC Health (NRC)vs › | $452.54M | 22.82 |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.54M | 25.00 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.56, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.64 | $-0.65 – $-0.63 | 3 | n/m |
| 2027-12-31 | $-0.60 | $-0.78 – $-0.43 | 4 | n/m |
| 2028-12-31 | $-0.53 | $-0.80 – $-0.33 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
